CUSIP: G3141W122
Q3 2022 13F Holders as of 30 Sep 2022
-
Type / Class
-
Equity / *W EXP 10/23/202
-
Total 13F shares
-
1,337,052
-
Share change
-
-30,995
-
Total reported value
-
$385,719
-
Price per share
-
$0.04
-
Number of holders
-
14
-
Value change
-
-$1,819
-
Number of sells
-
4
Quarterly Holders Quick Answers
What is CUSIP G3141W122?
CUSIP G3141W122 identifies EUCRW - EUCRATES BIOMEDICAL ACQU COR - *W EXP 10/23/202 in SEC institutional holdings data.
Need full ownership history?
Open the full security ownership history page.
Explore More Reporting Periods
Jump to adjacent filing periods for faster comparison and easier crawl discovery.
-
Newer quarter:
Q4 2022
-
Previous quarter:
Q2 2022
Recent filing periods for CUSIP G3141W122:
Institutional Holders of EUCRATES BIOMEDICAL ACQU COR - *W EXP 10/23/202 (EUCRW) as of Q3 2022
As of 30 Sep 2022,
EUCRATES BIOMEDICAL ACQU COR - *W EXP 10/23/202 (EUCRW) was held by
14 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
1,337,052 shares.
The largest 10 holders included
DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C), 683 Capital Management, LLC, Altium Capital Management LP, Granite Point Capital Management, L.P., Magnetar Financial LLC, COWEN AND COMPANY, LLC, Arena Investors LP, AQR Arbitrage LLC, Radcliffe Capital Management, L.P., and JANE STREET GROUP, LLC.
This page lists
14
institutional shareholders reporting positions in this security
for the Q3 2022 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.